Non-secretory multiple myeloma: from biology to clinical management

por Dupuis, Megan Murray, Tuchman, Sascha A
Publicado 2016

Lenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma

por Tuchman, S. A., Chao, N. J., Gasparetto, C. G.
Publicado 2012

HER-2/neu and CD117 (c-kit) overexpression in patients with pesticide exposure and extensive stage small cell lung carcinoma (ESSCLC)

por Potti, Anil, Ganti, Apar Kishor, Tuchman, Sascha A, Sholes, Kaley, Langness, Eric, Koka, Vijay, Koch, Michael
Publicado 2005

Supportive Care and Symptom Management for Patients With Immunoglobulin Light Chain (AL) Amyloidosis

por Jensen, Christopher E., Byku, Mirnela, Hladik, Gerald A., Jain, Koyal, Traub, Rebecca E., Tuchman, Sascha A.
Publicado 2022

Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma

por Laubach, Jacob P., Tuchman, Sascha A., Rosenblatt, Jacalyn M., Mitsiades, Constantine S., Colson, Kathleen, Masone, Kelly, Warren, Diane, Redd, Robert A., Grayson, Dena, Richardson, Paul G.
Publicado 2021

Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis

por Gertz, Morie, Abonour, Rafat, Gibbs, Sarah N, Finkel, Muriel, Landau, Heather, Lentzsch, Suzanne, Lin, Grace, Mahindra, Anuj, Quock, Tiffany, Rosenbaum, Cara, Rosenzweig, Michael, Sidana, Surbhi, Tuchman, Sascha A, Witteles, Ronald, Yermilov, Irina, Broder, Michael S
Publicado 2023

Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma

por Usmani, Saad Z., Karanes, Chatchada, Bensinger, William I., D’Souza, Anita, Raje, Noopur, Tuchman, Sascha A., Sborov, Douglas, Laubach, Jacob P., Bianchi, Giada, Kanagavel, Dheepak, Saleem, Rao, Dubin, Franck, Campana, Frank, Richardson, Paul G.
Publicado 2021

Physical Function, Psychosocial Status, and Symptom Burden Among Adults with Plasma Cell Disorders and Associations with Quality of Life

por Jensen, Christopher E, Vohra, Sanah N, Nyrop, Kirsten A, Deal, Allison M, LeBlanc, Matthew R, Grant, Shakira J, Muss, Hyman B, Lichtman, Eben I, Rubinstein, Samuel M, Wood, William A, Mangieri, Nicholas J, Jamison, Lee, Tuchman, Sascha A
Publicado 2022

A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma

por Ramasamy, Karthik, Nooka, Ajay, Quach, Hang, Htut, Myo, Popat, Rakesh, Liedtke, Michaela, Tuchman, Sascha A., Laubach, Jacob, Gasparetto, Cristina, Chanan-Khan, Asher, Hertzberg, Mark, deMario, Mark, Nueesch, Eveline, Chesne, Evelyne, Franjkovic, Izolda, Lechner, Katharina, Kornacker, Martin, Cho, Hearn Jay
Publicado 2021

Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antigen treatment

por Baljevic, Muhamed, Gasparetto, Cristina, Schiller, Gary J., Tuchman, Sascha A., Callander, Natalie S., Lentzsch, Suzanne, Monge, Jorge, Kotb, Rami, Bahlis, Nizar J., White, Darrell, Chen, Christine I., Sutherland, Heather J., Madan, Sumit, LeBlanc, Richard, Sebag, Michael, Venner, Christopher P., Bensinger, William I., Biran, Noa, DeCastro, Andrew, Van Domelen, Dane R., Zhang, Chris, Shah, Jatin J., Shacham, Sharon, Kauffman, Michael G., Bentur, Ohad S., Lipe, Brea
Publicado 2022

Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients

por Gasparetto, Cristina, Schiller, Gary J., Tuchman, Sascha A., Callander, Natalie S., Baljevic, Muhamed, Lentzsch, Suzanne, Rossi, Adriana C., Kotb, Rami, White, Darrell, Bahlis, Nizar J., Chen, Christine I., Sutherland, Heather J., Madan, Sumit, LeBlanc, Richard, Sebag, Michael, Venner, Christopher P., Bensinger, William I., Biran, Noa, Ammu, Sonia, Ben-Shahar, Osnat, DeCastro, Andrew, Van Domelen, Dane, Zhou, Tianjun, Zhang, Chris, Bentur, Ohad S., Shah, Jatin, Shacham, Sharon, Kauffman, Michael, Lipe, Brea
Publicado 2021